HIV感染献血者并发感染HBV、HCV及梅毒调查分析

目的:了解曲靖市无偿献血人群中艾滋病病毒(HIV)感染者并发感染乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)和梅毒的状况。方法:应用酶联免疫吸附试验(ELISA),对HIV感染献血者检测HBsAg、抗-HCV、抗-TP。结果:133例HIV感染献血者中,HBV感染率为1.5%,HCV感染率为10.5%,梅毒感染率为7.5%。结论:曲靖市HIV感染的献血者中,并发HCV和梅毒感染率高,而并发HBV感染率较低。     

单采血浆和输血途径感染HIV的患者中HBV和HCV感染状况

目的 了解单采血浆和输血途径感染艾滋病病毒(HIV)的人群中,乙型肝炎(乙肝)病毒(HBV)、丙型肝炎(丙肝)病毒(HCV)的感染状况. 方法 应用酶联免疫吸附试验(ELISA),对825 名HIV阳性的单采血浆献血员和受血者,检测乙肝病毒表面抗原(HBsAg)和丙肝病毒抗体(抗-HCV). 结果 单采血浆和输血途径感染HIV的人群中,HBV、HCV的感染率分别为3.76%、72.24%.其中单采血浆献血员中,HCV感染率(81.85%)高于输血人群(56.03%),而HBV感染率(1.54%)低于输血人群(7.49%)(P均＜0.01). 结论 在单采血浆和输血途径感染HIV的患者中,有很高的HCV感染率,而HBV感染率较低.     

HIV/AIDS病人合并HBV和HCV感染状况分析

目的分析艾滋病病毒(HIV)感染者和艾滋病(AIDS)病人(简称HIV/AIDS病人)合并感染乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)的流行现状及其特点,为AIDS的防控和治疗提供科学依据。方法选取2011-2015年期间准备开始高效抗反转录病毒治疗(HAART)的HIV/AIDS病人986例,采用酶联免疫吸附试验检测HIV/AIDS病人血液中的乙型肝炎表面抗原(HBsAg)和/或丙型肝炎病毒抗体(HCV-Ab)。计数资料样本率的比较采用χ2检验,计量资料的比较采用t检验。结果 HIV/AIDS病人合并HBV感染率为6.06%(59/974),合并HCV感染率为4.12%(40/972),合并HBV/HCV双重感染率为0.42%(4/960),HIV/AIDS病人合并HBV和HCV感染率的差异无统计学意义。血液途径感染HIV者的合并HBV感染率为15.79%,合并HCV感染率为41.03%,均显著高于性途径合并HBV和HCV的感染率(5.01%和1.68%)。合并乙型肝炎病人的CD4+T淋巴细胞200个/μL的比例,明显高于合并丙型肝炎病人CD4+T淋巴细胞200个/μL的比例。合并HBV和HCV感染的病人的天冬氨酸转氨酶、丙氨酸转氨酶、总胆红素均没有显著性差异。结论郑州市HIV/AIDS病人合并HBV和HCV总体感染率低于普通人群,HIV合并HBV/HCV感染的趋势有所控制。但血液途径感染HIV者合并HBV和HCV感染率仍高于普通人群,要加大防控力度。     

佑安医院HIV/AIDS病人中HBV HCV及TP感染情况分析

目的分析佑安医院艾滋病病毒(HIV)感染者/艾滋病(AIDS)病人(简称HIV/AIDS病人)中,乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)及梅毒螺旋体(TP)的共感染情况,为HIV的防控和综合治疗提供科学依据。方法回顾性分析2013年6月至2014年6月,在佑安医院艾滋病门诊接受艾滋病抗病毒治疗的1314例HIV/AIDS病人,调查抗病毒治疗基线时HBV、HCV及TP的共感染情况。结果1314例患者中,男性1255例(95.5%),女性59例(4.5%),平均年龄33.43岁(16~80岁)。其中1070例检测了抗TP,阳性率38.1%(408例);1164例检测了HBV感染标志物,HBsAg阳性率5.9%(69例),HBV标志物全阴性400例(34.4%);1161例检测了抗HCV,阳性率2.2%(25例)。经性途径感染HIV者TP共感染率高,分别有32.8%(368/1122)男男性行为者和22.9%(25/109)异性性行为者抗TP阳性。结论需要加强HIV感染者中HBV、HCV的筛查,以保证抗HIV治疗的顺利进行。经性途径感染HIV的患者中TP感染率较高,需积极干预。     

乙型与丙型肝炎病毒双重感染的研究进展

我国是病毒性肝炎发病率较高的国家,属于乙型肝炎病毒(HBV)感染高流行区,同时我国丙型肝炎病毒(HCV)感染率也很高。HBV与HCV具有相同的传播途径,因此HBV/HCV双重感染(HBV/HCV dual infection)较多见,HBV/HCV双重感染不但加     

深圳市初治HIV感染者合并HBV感染率及特征分析

目的了解深圳市初治HIV感染者合并HBV感染率、特征及HBV易感率。方法以2015—2018年深圳市第三人民医院收治的未接受过抗反转录病毒治疗的成年HIV感染者作为研究对象,收集其基本特征和临床资料,分析纳入对象合并HBV的感染率、合并感染者特征及HBV易感率。结果共纳入4666例初治HIV感染者,合并HBV感染率为10.46%(488/4666);合并感染率随年龄升高、CD4细胞计数的降低和WHO HIV临床分期的加重均呈现逐渐增高的趋势(P均<0.05)。不同HBV DNA水平分组间HIV RNA的差异以及不同HIV RNA水平分组间HBV DNA的差异均无统计学意义(P均>0.05)。HIV/HBV共感染者以HBeAg阴性所占比例较高(76.2%),但HBeAg阳性者ALT异常率高于HBeAg阴性者(31.03%vs.15.86%,P<0.05)。深圳市HIV感染者HBV易感率为24.73%(1154/4666),女性高于男性(31.56%vs.24.16%,P<0.05),15~24岁在各年龄组中最高,为29.00%(P<0.05)。结论深圳市初治HIV感染者合并HBV感染率和HBV易感率均较高。年龄较大和病程较重的HIV感染者合并HBV感染率最高。建议对HIV感染者常规进行治疗前HBV的筛查、临床状态的评估及用药后的监测。对乙型肝炎(乙肝)五项检测均为阴性的HBV易感者建议接种乙肝疫苗。     

HIV感染者中HCV及HBV感染状况的研究

目的 了解HIV感染者中HCV、HBV的感染状况。方法 对197例HIV感染者中的HCV、HBV感染情况进行了血清流行病学调查研究。结果 HIV感染者中HCV的感染率为90.35％,HBV的总感染率为51.94％,HIV、HCV、HBV三重感染率为49.35％。结论 HIV感染者中有极高的HCV感染率,有较高的HBV感染率。     

经血和经性传播的人类免疫缺陷病毒感染者乙、丙型肝炎病毒重叠感染比较

我国目前传播人类免疫缺陷病毒(HIV)主要途径为经血传播,如静脉吸毒,输血等,我们曾报道了经血传播HIV和HBV/HCV重叠感染的特征[1,2 ] 。而国外报道HIV传播的主要途径为性途径,在经性途径传播的HIV感染者中HBV/HCV重叠感染状况和感染特征不甚明确,我们以HIV感染的德国男性同性恋者为研究对象,首先对其HBV/HCV重叠感染状况进行调查,并总结了经性和经血传播HIV感染者HBV/HCV重叠感染特点及差异。对象和方法一、研究对象1992年1月～2 0 0 0年12月HIV感染的德国男性同性恋者4 9例,我国经血传播HIV感染者6 2例,取静脉血3ml,- …     

广西桂中地区艾滋病患者乙型和丙型肝炎病毒感染调查研究

目的了解广西桂中地区人类免疫缺陷病毒(HIV)/艾滋病(AIDS)患者合并乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)感染的情况。方法调查分析我院2007-01～2009-12确诊的2 342例AIDS患者临床资料。结果 HIV/HBV、HIV/HCV、HIV/HBV/HCV共感染率分别为16.8%、22.5%、2.5%,其中吸毒和性传播者HIV/HCV感染率分别为74.7%和8.0%、HIV/HBV感染率分别为15.6%和17.2%、HIV/HBV/HCV感染率分别为7.8%和1.0%。结论广西桂中地区HIV/HBV共感染在性传播和吸毒传播者中差异无统计学意义,HIV/HCV、HIV/HBV/HCV共感染差异有统计学意义,应采取措施控制其传播。     

HIV/HCV混合感染者与HCV感染者感染HCV基因型分析

目的使用二代测序技术检测广州地区人类免疫缺陷病毒(HIV)/丙型肝炎病毒(HCV)混合感染者和HCV感染者HCV基因型,了解本地区HCV基因型的流行特点。方法在233例HCV感染者中,包括95例HIV/HCV混合感染者和138例HCV感染者,使用Illumina Miseq平台PE300模式对HCV Core和NS5B片段进行测序,采用生物信息学分析确定HCV基因型,对测序结果提示混合基因型感染的样本,使用NS5A基因型特异引物进行验证。结果 HIV/HCV混合感染者静脉吸毒感染构成比显著高于HCV感染者(77.7%对19.6%P0.001),HCV感染者输血感染的构成比显著高于HIV/HCV混合感染者(48.6%对3.2%P0.001);HIV/HCV混合感染者HCV Core基因片段平均数据量为(15456±6689) reads,HCV感染者为(14323±5321) reads,两组无显著差异(P0.05);HIV/HCV混合感染者HCV NS5B基因片段平均数据量为(16432±3467) reads,HCV感染者为(17611±5632) reads,也无显著差异(P0.05);本组228例(97.9%)HCV感染者为单一HCV基因型感染,HIV/HCV混合感染者HCV 6a型和3b型感染率显著高于HCV感染者(分别为47.4%对26.8%,P=0.001和13.7%对3.6%,P=0.005),HCV 1b型感染率显著低于HCV感染者(20.0%对59.4%,P0.001);在233例入组的HCV感染者中,发现5例(2.1%)为混合基因型感染,其中4例为HIV/HCV混合感染者,1例为HCV感染者。结论广州地区HIV/HCV混合感染者与HCV感染者感染HCV基因型构成比存在差异,其临床意义还需要探讨。     

Les hépatites virales B et C chez les porteurs du virus de l’immunodéficience humaine à Bukavu (Sud-Kivu), République démocratique du Congo

Objective

To determine the prevalence of the co-infection of hepatitis B (HBV) and C (HCV) viruses with the human immunodeficiency virus (HIV) in individuals living with HIV in comparison with a control group HIV(?).

Methods

During a transversal study from March until August 2008 in Bukavu, we collected 209 sera from individuals living with HIV, mean age 36.7 ± 11.7 years with 67.4% females and 51% under antiretroviral (ARV) drugs. The control group consisted of 211 subjects: 143 voluntary blood donors and 68 patients, all HIV (?), with a mean age of 37.3 ± 11.3 years.

Results

The co-infection HIV-HBV affected 8% of the individuals living with HIV. The latter had no increased risk of HBV seropositivity in comparison with the control group: odds ratio (OR) of 1.0 [95% confidence interval (CI): 0.5–2.2]. HCV infection affected 4% of the control group versus 10% in the group of individuals living with HIV, which had a three times increased risk of positive serology for HCV in comparison with the control group: OR = 2.7; P = 0.02 (95% CI: 1.1–6.8). Co-infection either with HBV or HCV affected 18% of the group HIV (+). Two patients (1%) of the latter group had the markers for both hepatitis viruses. In the HIV (?) group, co-infection with HBV and HCV reached 12%.

Conclusion

Owing to the relative high prevalence of HBV and HCV co-infection, we recommend the systematic screening for hepatitis markers in the patients infected by HIV.     

Prevalence of occult hepatitis B & C in HIV patients infected through sexual transmission.

BACKGROUND: Prevalence of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) markers including active and occult infection has not been described in diverse cohorts among HIV-infected patients in India. Earlier studies have explained the role of HBV/HCV co-infection in cohorts of injection drug users (IDUs) but the sexual co-transmission of HBV/ HCV is not completely understood. OBJECTIVE: The objective of this study was to assess the prevalence of occult HBV & HCV infection in HIV positive sexually acquired transmission risk group. MATERIALS AND METHODS: 58 sexually acquired HIV positive patients were taken up for the study of occult HBV/HCV co-infection. Data on demographics, sexual behaviour, sexually transmitted diseases (STD), medical history, laboratory tests viz., serum ALT and CD4 count were recorded. HBV serology included HBsAg, anti HBs, IgG anti HBc and HBV DNA (PCR). HCV serology included anti HCV & HCV RNA (RT-PCR). RESULTS: Occult HBV infection (HBV DNA) was observed in 12.2% (7/58 with HBsAg -ve and IgG anti HBc +ve subjects) while an overall prevalence of HBV DNA was 13.7% (12% occult & 1.7% in HBsAg+ve patients). Out of 58 HIV positive patients 29.3% demonstrated reactivity for any marker of past or current HBV infection. (HBsAg 1.7%, anti HBs 10.3% anti HBc IgG 17.2%). 4/58 (6.8%) revealed anti HCV positivity along with HCV RNA positivity by RT-PCR while 6/58 (10.3%) individuals revealed an occult HCV infection (anti HCV negative). The overall HCV RNA prevalence was 17.2%. 2 out of 58 (3.4%) individuals were positive for occult infection of both HBV DNA & HCV RNA (Triple infection HIV/HBV/ HCV). The HBV/HCV co-infected group (n = 18) showed a significantly high ALT (114.3 + 12.3 U/I) & low CD4 count (202.5 + 33.7 cells/mm3). The percent prevalence of HBV/ HCV co-infection was higher in the illiterate group, in men less than 30 years of age, and in those who were married and exhibited polygamous activity. CONCLUSIONS: The study demonstrated that in HIV infected patients testing only serological viral markers like HBsAg, antiHBcIgG & anti HCV, fails to identify the true prevalence of co-infection with HBV & HCV. Qualitative PCR for HBV DNA & HCV RNA detects co-infection in patients who are negative for serological markers. Also, in subjects who had only a sexual risk factor for parenterally transmitted infections, HIV may enhance the sexual transmission of HBV and HCV.     

Seroprevalence of HCV and its co-infection with HBV and HIV among liver disease patients of South Tamil Nadu

AIM: To determine the seroprevalence of hepatitis C virus (HCV) and its co-infection with hepatitis B virus (HBV), hepatitis delta agent (HDV) and human immunodeficiency virus (HIV) among liver disease patients of south Tamil Nadu.METHODS: A total of 1012 samples comprising 512 clinically diagnosed cases of liver disease patients and 500 apparently healthy age and sex matched individuals were screened for Hepatitis C virus (anti HCV and HCV RNA), Hepatitis B virus (HBsAg), Hepatitis delta agent (anti HDV) and Human immuno virus (antibodies to HIV-1 and HIV-2) using commercially available enzyme linked immunosorbent assay kits. HCV RNA was detected by RT-PCR. Liver function tests like ALT, AST, GGT, ALP, bilirubin and albumin were also studied.RESULTS: The seroprevalence of HCV was found to be 5.6% among liver disease patients by ELISA. 27/512, 49/512 and 12/512 patients were positive for HIV, HBV & HDV respectively. Co-infection of HCV & HBV was found in 8 patients, with 6 for HCV & HIV and 4 for HCV, HBV & HIV co-infections. Sex-wise analysis showed that HIV, HCV & HBV and HCV & HIV co-infection was high among females whereas for HBV it was high in males. The mean ALT and AST in HCV positive cases were 42.1 ± 8.3 and 49 ± 10.1. In people co-infected with HCV & HBV or HCV & HIV or HCV, HBV & HIV the mean ALT of 58.0 ± 03.16, 56.78 ± 4.401 and 64.37 ± 4.01 respectively.CONCLUSION: We strongly recommend routine test of the blood for HCV in addition to HBV and HIV. We also recommend individualized counseling to identify those at risk and testing for those who want it. Improved surveillance and periodic epidemiological studies will have to be undertaken to monitor and prevent these blood-borne viruses.     

Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort

AIM:To determine the rates and impact of hepatitis B virus(HBV) and hepatitis C virus(HCV) infections on response to long-term highly active antiretroviral therapy(HAART) in a large human immunodeficiency virus(HIV) population in Nigeria.METHODS:HBV and HCV as well as HIV infections are endemic in sub Saharan Africa.This was a retrospective cohort study of 19 408 adults who were recruited between June 2004 and December 2010 in the AIDS Prevention Initiative in Nigeria in Nigeria programme at Jos University Teaching Hospital.Serological assays,including HBV surface antigen(HBsAg) and hepatitis C antibody were used to categorise hepatitis status of the patients.HBsAg was determined using enzyme immunoassay(EIA)(Monolisa HBsAg Ultra3;Bio-Rad).HCV antibody was tested using third generation EIA(DIA.PRO Diagnostic,Bioprobes srl,Milan,Italy).HIV RNA levels were measured using Roche COBAS Amplicor HIV-1 monitor test version 1.5(Roche Diagnostics,GmbH,Mannheim,Germany) with a detection limit of 400 copies/mL.Flow cytometry was used to determine CD4+ cell count(Partec,GmbH Munster,Germany).Comparison of categorical and continuous variables were achieved using Pearson’s χ 2 and Kruskal Wallis tests respectively,on MedCalc for Windows,version 9.5.0.0(MedCalc Software,Mariakerke,Belgium).RESULTS:With an overall hepatitis screening rate of over 90% for each virus;HBV,HCV and HBV/HCV were detected in 3162(17.8%),1983(11.3%) and 453(2.5%) HIV infected adults respectively.The rate of liver disease was low,but highest among HIV monoinfected patients(29,0.11%),followed by HBV coinfected patients(15,0.08%).Patients with HBV coinfection and triple infection had higher log 10 HIV RNA loads(HBV:4.6 copies/mL vs HIV only:4.5 copies/mL,P<0.0001) and more severe immune suppression(HBV:645,55.4%;HBV/HCV:97,56.7%) prior to initiation of HAART compared to HIV mono-infected patients(1852,48.6%)(P<0.0001).Of 3025 patients who were 4.4 years on HAART and whose CD4 cell counts results at baseline and end of follow up were available for     

有偿献血员中艾滋病病毒、乙型肝炎和丙型肝炎病毒感染状况的研究

目的 探讨有偿献血员艾滋病病毒(HIV)、丙型肝炎(丙肝)病毒(HCV)、乙型肝炎(乙肝)病毒(HBV)感染的特点。方法61份HIV阳性献血员及89份HIV阴性献血员的血清,经酶联免疫吸附试验(ELISA)检测HCV抗体(抗-HCV)及HBV血清学标志物,比较两组人群的HCV、HBV及HCV/HBV感染情况。结果HIV阳性献血员的抗-HCV阳性率为70.49％。乙肝病毒表面抗原(HBsAg)与抗体(抗-HBs)、乙肝病毒e抗原(HBeAg)与抗体(抗-HBe)、乙肝病毒核心抗体(抗-HBc)和HBV的阳性率分别为8.20％、29.51％、3.28％、44.26％、11.4896、47.54％;而HIV阴性献血员的抗-HCV阳性率为19.10％,HBsAg、抗-HBs、HBeAg、抗-HBe、抗-HBc、HBV的阳性率分别为2.25％、38.20％、1.12％、47.19％、6.74％、47.19％。经统计学分析,两组人群的HCV、HCV/HBV感染率的差异有显著的统计学意义,而HBV血清学标志物则无显著性差异。结论 与HIV阴性献血员相比。HIV阳性献血员的HCV感染率很高,而HBV血清学标志物则无显著性差异。对献血员进行HBV检测而未检测HIV、HCV造成的选择偏倚,可能是中国中部一些省份HIV感染者HCV感染率高而HBV感染并不相应增高这一现象的原因之一。     

Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol

BACKGROUND/AIMS: We analyzed the characteristics of HIV infected patients who died from liver disease, focusing on hepatitis virus co-infection. METHODS: One-hundred and eighty-five French hospital departments involved in HIV/AIDS management prospectively notified all deaths occurring in 2000. Patients whose hepatitis C (HCV) and hepatitis B (HBV) serostatus was known were classified as being infected by HCV alone, HBV alone (HBsAg positive), both HCV and HBV, or neither HCB nor HBV. RESULTS: Among 822 HIV infected patients, 29% were infected by HCV alone, 8% by HBV alone, and 4% by both HCV and HBV. The most frequent causes of death were liver disease (31% of cases) and AIDS (29%) among HIV-HCV co-infected patients, and AIDS (38%) and liver disease (22%) among HIV-HBV co-infected patients. Liver disease was a more frequent cause of death among patients co-infected by both HCV and HBV (44% of cases). Hepatocellular carcinoma was present in 15% of patients who died from liver disease, and was associated with HBV co-infection. Nearly half the patients who died from liver disease had more than 200 CD4/mm3. CONCLUSIONS: Liver disease is now a leading cause of death among HIV-HCV co-infected patients and is becoming an important cause of death among HIV-HBV co-infected patients. The risk of death from liver disease is highest in patients co-infected by both HCV and HBV.     

Characteristics of co-infections by HCV and HBV among Brazilian patients infected by HIV-1 and/or HTLV-1

BackgroundThe human retroviruses HIV-1 and HTLV-1 share the routes of infection with hepatitis viruses B and C. Co-infection by these agents are a common event, but we have scarce knowledge on co-infection by two or more of these agents.ObjectiveTo evaluate the characteristics and risk factors for co-infections by HBV and HCV in patients infected by HIV-1 or/and HTLV-1, in Salvador, Brazil.MethodsIn a case–control study we evaluated patients followed in the AIDS and HTLV clinics of Federal University of Bahia Hospital. Clinical and epidemiological characteristics were reviewed, and patients were tested for the presence of serological markers of HBV and HCV infections. HCV-infected patients were tested by PCR to evaluate the presence of viremia.ResultsA total of 200 HIV-1, 213 HTLV-1-infected, and 38 HIV-HTLV-co-infected individuals were included. HIV-infected patients were more likely to have had more sexual partners in the lifetime than other patients’ groups. HIV-HTLV-co-infected subjects were predominantly male. Patients infected by HTLV or co-infected had a significantly higher frequency of previous syphilis or gonorrhea, while HIV infection was mainly associated with HPV infection. Co-infection was significantly associated to intravenous drug use (IVDU). HBV and/or HCV markers were more frequently found among co-infected patients. HBV markers were more frequently detected among HIV-infected patients, while HCV was clearly associated with IVDU across all groups. AgHBs was strongly associated with co-infection by HIV-HTLV (OR = 22.03, 95% CI: 2.69–469.7), as well as confirmed HCV infection (p = 0.001). Concomitant HCV and HBV infection was also associated with retroviral co-infection. Patients infected by HTLV-1 had a lower chance of detectable HCV viremia (OR = 0.04, 95% CI: 0.002–0.85).ConclusionsInfection by HCV and/or HBV is frequent among patients presenting retroviral infection, but risk factors and prevalence for each infection are distinct for each agent. Retroviral co-infection increases the risk of a positive AgHBs, but HTLV-1 infection seems to increase the likelihood of HCV spontaneous clearance.     

Coinfection of hepatitis B and hepatitis C virus in HIV-infected patients in south India

AIM To screen for the co-infection of hepatitis B (HBV)and hepatitis C virus (HCV) in human immunodeficiency virus (HIV) infected patients insouthern India.METHODS Five hundred consecutive HIV infected patients were screened for Hepatitis B Virus (HBsAg and HBV-DNA) and Hepatitis C virus (anti-HCV and HCV-RNA)using commercially available ELISA kits; HBsAg, HBeAg/anti-HBe (Biorad laboratories, USA) and anti-HCV (Murex Diagnostics, UK). The HBV-DNA PCR was performed to detect the surface antigen region (pre S-S). HCV-RNA was detected by RT-PCR for the detection of the constant 5' putative non-coding region of HCV.RESULTS HBV co-infection was detected in 45/500 (9%)patients and HCV co-infection in 11/500 (2.2%) subjects.Among the 45 co-infected patients only 40 patients could be studied, where the detection rates of HBe was 55%(22/40), antiHBe was 45% (18/40) and HBV-DNA was 56% (23/40). Among 11 HCV co-infected subjects, 6(54.5%) were anti-HCV and HCV RNA positive, while 3(27.2%) were positive for anti-HCV alone and 2 (18%)were positive for HCV RNA alone.CONCLUSION Since the principal routes for HIV transmission are similar to that followed by the hepatotropic viruses, as a consequence, infections with HBV and HCV are expected in HIV infected patients.Therefore, it would be advisable to screen for these viruses in all the HIV infected individuals and their sexual partners at the earliest.     

山东省HIV与HCV共感染者的流行病学分析

目的了解丙型肝炎病毒（HCV）在山东省艾滋病病毒（HIV）感染者中的感染状况,分析HIV、HCV共感染者的流行病学特征。方法对2000-2010年底,山东省报告的HIV感染者/艾滋病（AIDS）病人确证时的血样进行HCV检测,选取现在存活的、年龄≥18岁的HIV感染者和AIDS病人为研究对象,通过研究对象HIV确证后的首次随访调查表,收集流行病学信息,进行单因素分析和多因素Logistic回归分析。结果 HIV与HCV共感染率为41.7%（842/2 021）。单因素分析发现,不同文化程度、不同性别、籍贯和传染途径、不同民族之间差异有统计学意义（P〈0.05）,在此基础上进行多因素的Logistic回归分析发现,性别、籍贯和感染途径是HIV/HCV共感染的独立危险因子。结论不同性别、籍贯和传染途径中HIV、HCV共感染率不同,应引起重视。